SOS1

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Retrieved on: 
Sunday, October 8, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Slate, Cancer, NYSE, Bristol Myers Squibb, Acquisition, Food, Cetuximab, KRAS, U.S. FDA, Cholangiocarcinoma, Central nervous system, Therapy, PRMT5, Accretion/dilution analysis, Disease, Morgan Stanley, FDA, VWAP, Doctor of Philosophy, Melanoma, Food and Drug Administration, MTAP, Kirkland & Ellis, CVR, Colorectal cancer, Chairperson, Science, Skadden, Arps, Slate, Meagher & Flom, News, Pancreatic cancer, MTA, Mirati Therapeutics, SOS1, MAPK, Centerview Partners, CNS, Life, BMY, Contingent value rights, PD-1, Patient, Financial toxicity, Pharmaceutical industry, Bank, NSCLC, Mirati

The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.
  • Mirati’s assets are a strong fit with Bristol Myers Squibb’s portfolio and innovative pipeline and represent an attractive opportunity to grow Bristol Myers Squibb’s oncology franchise.
  • Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio.
  • Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, August 8, 2023
PDAC, Docetaxel, KRAS, American Journal of Clinical Oncology, Marketing, MTA, Pharming, European Medicines Agency, Cholangiocarcinoma, New Drug Application, American Society of Clinical Oncology, SOS1, Cancer Discovery (journal), SAPPHIRE, Cancer, Clinical trial, Committee on Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Cetuximab, TPS, Trial of the century, Committee, EMA, ASCO, Conditional, Shanda, Journal, Outline, Patient, Investment, Manuscript, Meekness, Colorectal cancer, Committee for Medicinal Products for Human Use, Annual general meeting, MAA, Research, FDA, Pembrolizumab, Therapy, Society, Nivolumab, PRMT5, CHMP, Cryptocurrency, Communications satellite, Pharmaceutical industry, Nursing

SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • ET / 2:30 p.m. PT
    SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
  • Based on these results, the Company plans to discuss a tumor agnostic Accelerated Approval approach with FDA by year-end 2023.
  • Net reduction in cash, cash equivalents and short-term investments for the second quarter of 2023 was $122.9 million.
  • ET / 2:30 p.m. PT during which company executives will review financial information for the second quarter and provide corporate updates.

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Retrieved on: 
Monday, June 5, 2023
KRAS, Communication, MYC, Probability, CRC, DCR, SOS1, Clinical trial, Encorafenib, DDI, Trae tha Truth, BRAF, Research, SHP2, CNS, Cetuximab, RAS, Patient, EGFR, Colorectal cancer, ERK, SAN, HNSCC, HPV, UPR, EC, CPRS, Resuscitation, Safety, Pharmaceutical industry

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced promising preliminary Phase 1b data for ERK inhibitor ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC) and provided a portfolio update. Erasca will host a virtual investor event to discuss these updates today at 4:30 PM ET. To register for the event, please click here.

Key Points: 
  • Erasca will host a virtual investor event to discuss these updates today at 4:30 PM ET.
  • To register for the event, please click here .
  • “We are pleased that the early ERAS-007 clinical data continue to reinforce its potential to become a backbone for combination therapy,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder.
  • “Moreover, through our signal-seeking trials, we have tested three biological hypotheses: preventing in-pathway resistance, reversing in-pathway resistance, and targeting adjacent pathways.

Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Immortalised cell line, Pancreatic cancer, KRAS, CDK6, Inflammation, Neoplasm, SOS1, Cancer, Cell proliferation, Lung cancer, PRB, MEK, Publication, PDX, ASCO, Drug resistance, American Society of Clinical Oncology, Patient, EGFR, Colorectal cancer, SAN, Annual general meeting, PDF, GEF, Society, Breast cancer, Vaccine, Pharmaceutical industry, Medical imaging, MCF7, CDK4

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced two poster presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online. The presentations highlight preclinical data for bifunctional degraders of CDK4/6, including development candidate BTX-9341, for the treatment of estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-), and of son of sevenless homolog 1 (SOS1) for the treatment of KRAS mutant cancers.

Key Points: 
  • We look forward to advancing BTX-9341 towards clinical development to overcome drug resistance challenges faced by patients with solid tumors such as ER+/HER2- breast cancer."
  • The CDK4/6 bifunctional degraders were active in a CDK4/6 inhibitor resistant cell line and in multiple PDX CDK4/6 inhibitor resistant organoid models.
  • Biotheryx's SOS1 bifunctional degraders demonstrated antiproliferative effects across a range of KRAS-mutant cell lines.
  • Following the presentations at the meeting, PDF copies of the presentations and posters will be available in the " Publications and Presentations " section of Biotheryx's website.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Retrieved on: 
Monday, May 15, 2023
Carcinoma, Insurance, KRAS, AACR, NF2, N-acetyllactosaminide 3-alpha-galactosyltransferase, Quarter, Half-life, Therapeutic index, SOS1, BRAF, Fast Track, Bristol Myers Squibb, Research, MEK, SHP2, AstraZeneca, PI3K, TEAD, Plasma, Patient, Investment, RAS, Data, AHR, FDA, Collaboration, CRAF, IND, Conference, RAF, Vaccine, Pharmaceutical industry, Life insurance, Cryptocurrency, EGFR, Hippopotamus

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date
    BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.
  • “The start to 2023 has been full of exciting developments, including external clinical validation of the Hippo pathway and targeting TEAD.
  • “The first quarter also was the first time we shared the novel profile of IK-595, our MEK-RAF complex inhibitor.
  • Collaboration revenue was $5.3 million and $3.4 million for the three months ended March 31, 2023 and 2022, respectively.

Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Immortalised cell line, KRAS, AACR, CDK6, Inflammation, Neoplasm, CDK, SOS1, Cancer, Cell proliferation, PRB, American Association for Cancer Research, Publication, PDX, Drug resistance, Patient, SAN, Annual general meeting, PDF, GEF, Pancreatic tumor, Breast cancer, Pharmaceutical industry, Vaccine, MCF7, CDK4, IND

SAN DIEGO, April 17, 2023 /PRNewswire/ -- Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023. The presentations highlight preclinical data for bifunctional degraders of cyclin-dependent kinase (CDK) 4/6 for the treatment of solid tumors, and bifunctional degraders of son of sevenless homolog 1 (SOS1) for the treatment of KRAS mutant cancers. Additionally, the Company has nominated BTX-9341 as a development candidate for the CDK4/6 degrader program and has commenced IND-enabling studies.

Key Points: 
  • Additionally, the Company has nominated BTX-9341 as a development candidate for the CDK4/6 degrader program and has commenced IND-enabling studies.
  • "At AACR, we are proud to share encouraging preclinical data that highlights the potential of these exciting programs.
  • Similarly, in preclinical KRAS mutant cancer models, our SOS1 degraders resulted in greater than 90% degradation of SOS1 in tumors and led to significant tumor growth inhibition."
  • These data support the potential of SOS1 degradation as a valuable treatment option for a range of KRAS mutant cancers.

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Retrieved on: 
Monday, April 3, 2023
MTAP, AACR, MTA, Neoplasm, SOS1, American Association for Cancer Research, Mirati Therapeutics, Experiment, Congress, EGFR, SAN, Mirati, Therapy, Poster, PRMT5, Pharmaceutical industry, Communications satellite

SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

Key Points: 
  • Findings will be presented on April 17 at the American Association for Cancer Research (AACR 2023) Annual Congress as an oral presentation at 3:36 p.m. -3:51 p.m.
  • ET / 12:36 p.m.- 12:51 p.m. PT (Presentation #3499) during the Molecular Pathway Discovery and Translation in Solid Tumors mini session.
  • The full abstract for the presentation can be found here .
  • In addition, Mirati will share poster presentations featuring MRTX1719, the company's novel MTA cooperative PRMT5 inhibitor.

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Retrieved on: 
Tuesday, March 7, 2023
IND, RAF, ARAF, MEK, Cancer, NRAS, PI3K, AML, Poster, SOS1, RAS, Conference, AACR, American Association for Cancer Research, BRAF, MAPK, EGFR, Investigational New Drug, SHP2, KRAS, Lung, ERK, Phosphorylation, CRAF, Pharmaceutical industry

Dr. Zhang will present at a plenary session on Wednesday, March 8.

Key Points: 
  • Dr. Zhang will present at a plenary session on Wednesday, March 8.
  • The RAS pathway is implicated in at least half of a million new cancer diagnoses each year in the United States alone.
  • Presentation and poster details are as follows:
    More details on the conference program can be found on the conference website .
  • Ikena’s poster presentation will be available on the Resources section of the company’s website following the conference.

METiS Announces License Agreement with Evopoint Biosciences

Retrieved on: 
Friday, January 6, 2023
Technology, Research, Software, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Cancer, Drug discovery, Therapy, KRAS, Drug development, NCI, Voronoi, SOS1, AI, Entrepreneurship, Machine learning, National Cancer Institute, Pharmaceutical industry, Metis

METiS Therapeutics (METiS), a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a collaboration with Evopoint Biosciences Co., Ltd. (“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines.

Key Points: 
  • METiS Therapeutics (METiS), a Boston-area company integrating drug discovery and delivery with AI and machine learning, today announced they have entered a collaboration with Evopoint Biosciences Co., Ltd. (“Evopoint”), a biopharmaceutical company focused on discovering and developing innovative and transformative medicines.
  • Under the terms of the collaboration, METiS will receive an exclusive, worldwide, royalty-bearing license to develop and commercialize Evopoint’s SOS1 inhibitor program, a key regulatory protein/node in the RAS/MAPK pathway.
  • SOS1 is responsible for regulating the transition of KRAS from its “off” to “on” state, making it a compelling therapeutic target.
  • According to the National Cancer Institute (NCI), over 30% of all human cancers are driven by mutations of Ras genes.

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 22, 2022
Patient, TAM, Webcast, SAN, Judgement, PRMT5, Life, Conference, SOS1, Lung cancer, Therapy, Science, Cancer, MTA, Pharmaceutical industry, Mirati

SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.

Key Points: 
  • SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023.
  • David Meek , chief executive officer, will make a formal presentation, and answer questions about the Company at 9:00 a.m. P.T.
  • Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com .
  • This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. ("Mirati").